Open-Label, Multicenter, Single Ascending Dose Study to Assess the Safety of P-BCMA-101 in Subjects With Relapsed and/or Refractory Multiple Myeloma (MM)
Phase of Trial: Phase I
Latest Information Update: 08 Oct 2017
At a glance
- Drugs P-BCMA-101 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Poseida Therapeutics
- 20 Sep 2017 Status changed from not yet recruiting to recruiting.
- 18 Sep 2017 Status changed from planning to not yet recruiting.
- 21 Dec 2016 New trial record